Perivision, a Swiss Start-Up focused on the Ophthalmic side of medicine, recently asked BioPortUSA for help with the reimbursement side of things in the USA. “We knew we had to better understand how reimbursement for our product was going to work before we could approach potential investors,” said Patrick Kessel, CEO and Co-Founder. The company has developed a new kind of Visual Field Test (VFT)which can be used by Glaucoma patients as an alternative to the Humphrey VFT from Carl Zeiss. Perivision’s test is expected to take less time and cost less money to purchase than the Humphrey, making it potentially more attractive to patients and doctors alike. “As a glaucoma patient myself, I am very excited about the prospects for this new device, and can’t wait to use it,” said Mark Lesselroth, President and CEO of BioPortUSA.
PeriVision visual field testing software is running on calibrated Virtual Reality headsets. PeriVision’s patented machine learning algorithm cut down examination times to have more reliable results. The technology is being clinically tested and supported by key opinion leaders in ophthalmology.
BioPortUSA will be advising Perivision over the coming months on developing and executing their commercialization strategy.